title: Should we consider cancer/testis antigens NY-ESO-1, MAGE-A4 and MAGE-A1 as potential targets for immunotherapy in vulvar squamous cell carcinoma?
authors.forename: Jacek J
authors.initials: JJ
authors.lastname: Sznurkowski
authors.forename: Anton
authors.initials: A
authors.lastname: Zawrocki
authors.forename: Joanna
authors.initials: J
authors.lastname: Karczewska
authors.forename: Janusz
authors.initials: J
authors.lastname: Emerich
authors.forename: Wojciech
authors.initials: W
authors.lastname: Biernat
mesh_terms: D000951:Antigens, Neoplasm / Q000378:metabolism*; D002294:Carcinoma, Squamous Cell / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008565:Membrane Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D010446:Peptide Fragments / Q000037:antagonists & inhibitors / Q000378:metabolism*; D014846:Vulvar Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy
chemical_list: D000951:Antigens, Neoplasm; C104948:CTAG1B protein, human; C506530:MAGE-A1 protein (278-286), human; C095204:MAGEA4 protein, human; D008565:Membrane Proteins; D009363:Neoplasm Proteins; D010446:Peptide Fragments